Pfizer (PFE) Stock Soars on Trump’s Drug-Price Pact and $7.3B Weight-Loss Deal
Pfizer shares closed near a 52-week low at $24.40 on Sept. 30, 2025, despite Q2 revenue of $14.7 billion and adjusted EPS of $0.78, both above expectations. The company raised full-year EPS guidance and announced a $4.9 billion deal to acquire obesity drugmaker Metsera. President Trump unveiled a pact for Pfizer to cut U.S. drug prices and sell through a new TrumpRx site. FDA approved Pfizer’s updated COVID-19 vaccine for high-risk groups.